
United Therapeutics (UTHR) Stock Forecast & Price Target
United Therapeutics (UTHR) Analyst Ratings
Bulls say
United Therapeutics is supported by a durable treprostinil franchise that is now diversified across inhaled, parenteral, and oral routes, giving physicians flexibility and underpinning a record $503.8M Tyvaso quarter in 3Q26, with Tyvaso DPI alone rising to $378.5M. The outlook is further strengthened by improving PH-ILD momentum after the Yutrepia settlement, which reduces competitive pressure, plus the April 26, 2027 FDA decision for Tyvaso in IPF, a large unmet market of about 100K U.S. patients that could meaningfully expand the addressable opportunity. Additional upside comes from ralinepag, which cut clinical worsening risk by 55% in Phase 3 and has a June 24, 2027 FDA target date, while the company’s broader pipeline and share buybacks support long-term growth and capital returns.
Bears say
United Therapeutics is facing a more challenging competitive and regulatory backdrop as long-term upside from its prostacyclin franchise is pressured by emerging treprostinil alternatives, including TPIP’s once-daily dosing advantage versus Tyvaso’s four-times-daily regimen. The company’s core risk is that TPIP could improve convenience and adherence if it succeeds, while its own soft-mist inhaler, Tresmi, has already seen its NDA filing pushed to 2027, signaling slower execution and delaying a potential lifecycle extension. More broadly, downside remains tied to clinical execution, regulatory uncertainty, intellectual property risk, and pricing pressure, all of which threaten a business that derives the majority of revenue in the United States and depends heavily on Tyvaso DPI.
This aggregate rating is based on analysts' research of United Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
United Therapeutics (UTHR) Analyst Forecast & Price Prediction
Start investing in United Therapeutics (UTHR)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About United Therapeutics (UTHR) Forecast
United Therapeutics (UTHR) Analyst Forecast & Price Prediction
Start investing in United Therapeutics (UTHR)
Order type
Buy in
Order amount
Est. shares
0 shares